10 April 2023 - - French laboratory Horus Pharma, which is specialised in ophthalmology, has taken a major step in its European expansion strategy with the opening of its new subsidiary, the company said.

From its base in Stockholm, Sweden, Horus Pharma Nordic will cover Sweden, Norway, Finland and Denmark, which between them have nearly 30 m inhabitants.

Horus Pharma develops, patents and markets preservative-free eye and eyelid care products and solutions.

The Group focuses on using its medical and scientific know-how to offer physicians innovative therapeutic solutions that have patient safety as a top priority. Horus Pharma is headquartered in Nice, France and currently has a presence in Spain, the Benelux and Switzerland.

The new Nordic subsidiary is the next step forward.

During the coming year Horus Pharma's full range of products, which includes medical devices for treating glaucoma, allergies, inflammation, dry eye, and surgical and peri-surgical solutions as well as cosmetic products for eyelid hygiene, will progressively become available on the Nordic market.

Horus Pharma, founded in 2003, is an independent company acknowledged for its expertise in developing preservative-free ophthalmology products and a key player on the French and European market.

Through its active R&D programme the Group improves patients' everyday lives by developing innovative solutions and products for all segments of the ophthalmology market.

Horus Pharma distributes its products throughout France from its headquarters in Saint-Laurent du Var near Nice, in Belgium, the Netherlands, Luxembourg, Spain, Switzerland and now the Nordic countries through subsidiaries, and in many other countries through distribution agreements.

Right from its inception, the Eco' Ophtalmo programme has embedded ecology in Horus Pharma's culture.

The Group has always been committed to constantly seeking new ways to reduce its ecological footprint through its strategy of innovation, partnerships, and initiatives that encourage and support ecologically responsible practices so they become more widespread in its industry.

The group has two main objectives: reducing the environmental footprint and raising ophthalmologists' awareness of the environmental impact of medical practices through collaborations and the development of joint actions.

The group's projects include significant and ambitious initiatives, such as an environmental and social commitment to reach Plastic Net Zero and develop recyclable packaging.